Related Experiment Video
Updated: Jan 23, 2026

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma
Kehua Zhou1, Christos Fountzilas2
1Catholic Health System Internal Medicine Training Program, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14214, USA. kehuazho@buffalo.edu.
Abstract:
Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers worldwide; most patients are diagnosed with advanced disease for which there is no known cure. Tremendous progress has been made over the past decade in the development of new agents for HCC, including small-molecule kinase inhibitors such as sorafenib, lenvatinib, cabozantinib, regorafenib, and monoclonal antibodies like ramucirumab, nivolumab, and pembrolizumab. Ideal use of these agents in clinics has improved the long-term outcome of patients with advanced HCC as well as introduced unique toxicities that can affect quality of life. These toxicities usually are thought to be partially related to cirrhosis, a major risk factor for the development of HCC and a pathophysiological barrier complicating the optimal delivery of antineoplastic therapy. Additionally, side effects of medications together with advanced HCC symptoms not only decrease quality of life, but also cause treatment interruptions and dose reductions that can potentially decrease efficacy. Physicians caring for patients with advanced HCC are called to optimally manage HCC along with cirrhosis in order to prolong life while at the same time preserve the quality of life. In this review, we aimed to summarize outcomes and quality of life with the use of modern systemic treatments in advanced HCC and provide a physician reference for treatment toxicity and cirrhosis management.
Insights
New systemic treatments improve outcomes for advanced hepatocellular carcinoma (HCC), but managing unique toxicities alongside cirrhosis is crucial for maintaining patient quality of life and treatment efficacy.
Area of Science:
- Hepatology and Oncology
- Clinical Pharmacology
Background:
- Hepatocellular carcinoma (HCC) is a prevalent cancer often diagnosed at advanced stages with limited curative options.
- Recent advancements include targeted therapies like kinase inhibitors (sorafenib, lenvatinib) and immunotherapies (nivolumab, pembrolizumab) for advanced HCC.
- Cirrhosis, a common comorbidity, complicates treatment delivery and can exacerbate drug toxicities, impacting patient quality of life.
Purpose of the Study:
- To review the efficacy and quality-of-life outcomes associated with modern systemic therapies for advanced HCC.
- To provide clinicians with a reference for managing treatment-related toxicities in the context of cirrhosis.
- To guide optimal management strategies balancing survival benefits and quality of life for advanced HCC patients.
Main Methods:
- Systematic review of recent clinical trials and observational studies on systemic agents for advanced HCC.
- Analysis of reported patient outcomes, including overall survival, progression-free survival, and quality-of-life metrics.
- Evaluation of toxicity profiles and management strategies for common side effects, considering the impact of cirrhosis.
Main Results:
- Modern systemic treatments have demonstrated improved long-term outcomes for patients with advanced HCC.
- Treatment-related toxicities are common and can significantly affect patient quality of life, necessitating careful management.
- Cirrhosis presents a significant challenge, potentially influencing drug efficacy and toxicity, and requiring tailored therapeutic approaches.
Conclusions:
- Optimal management of advanced HCC requires a multidisciplinary approach, integrating modern systemic therapies with vigilant toxicity monitoring and cirrhosis management.
- Balancing the benefits of novel agents with the risks of side effects is essential for preserving quality of life in patients with advanced HCC and cirrhosis.
- Further research is needed to refine treatment strategies and supportive care for this complex patient population.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
10:35Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
Published on: September 25, 2013
Related Concept Videos
Characteristics of Life
Half-life of a Reaction
The Tree of Life - Bacteria, Archaea, Eukaryotes
The Angiosperm Life Cycle
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...